A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer.
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2018
At a glance
- Drugs Rabusertib (Primary) ; Pemetrexed
- Indications Cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 11 Apr 2012 Results published in Investigational New Drugs.
- 30 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.